Donor potential to exert NK cell alloreactivity has been shown to confer survival advantage in haploidentical hematopoietic cell transplantation for hematological malignancies. We investigated killer immunoglobulin receptor (KIR) ligand incompatibility in 40 children receiving haploidentical transplantation for primary immunodeficiencies. The conditioning regimen consisted of busulfan and cyclophosphamide. T-cell depletion of the graft used complement-dependent lysis or CD34 þ selection. Two patients died in the first month. The remaining 38 patients were divided into those with (n ¼ 13) and those without (n ¼ 25) donor potential to exert NK cell alloreactivity. Engraftment was similar in the two groups (61.5 and 64%, respectively). The incidence of grade II-IV acute graft-versus-host disease (GVHD) tended to be lower in the group with donor potential to exert NK cell alloreactivity, but the difference was not significant. In conclusion, in this series of patients with primary immunodeficiencies, donor potential to exert NK cell alloreactivity was not associated with significant advantages in engraftment and prevention of acute GVHD.
NK cell alloreactivity is the result of the differential cell surface expression of inhibitory and activating receptors, mostly belonging to the killer immunoglobulin receptor (KIR) family, with specificity for HLA class I determinants called KIR epitopes. Every NK cell expresses one or more inhibitory receptors which recognize and engage their ligands on the surface of the target cell, thereby initiating an inhibitory signal which prevents NK cells from killing healthy autologous cells (for reviews, see Parham . The most prevalent and dominant patterns of NK alloreactivity are those due to recognition by the KIR2DL1 and KIR2DL2/3 receptors of a dimorphism at position 80 of HLA-C a chain. KIR3DL1 recognizes an epitope on HLA-B molecules sharing the Bw4 supertype, and KIR3DL2 recognizes HLA-A3/A11 alleles. In the context of hematopoietic cell transplantation (HCT), donor-vs-recipient NK alloreactivity occurs when donor NK cells express inhibitory receptors, which do not recognize recipientmismatched class I molecules. In the absence of their specific inhibitory ligands, these NK cells will kill recipient lymphohematopoietic cells. NK cell killing of residual malignant cells might therefore be related to a graft-versus-leukemia (GVL) effect. Furthermore, NK killing of recipient T cells could improve engraftment and reduce the incidence of GVHD. Indeed, previous reports have shown that NK alloreactivity could prevent rejection and severe aGVHD, and increase disease-free survival in patients receiving haploidentical 3 or unrelated 4 HCT for hematological malignancies. As NK alloreactivity between donor and recipient can be predicted from their HLA class I genotype, we retrospectively evaluated 40 donor/recipient pairs in haploidentical transplants for children with inherited disorders. The aim was to determine whether potential NK alloreactivity might improve transplantation outcomes. Owing to their young age and their poor clinical status at time of transplantation, these children are not able to tolerate highintensity conditioning regimen (CR), and are more prone to graft rejection or GVHD. Therefore, a beneficial effect of NK alloreactivity would be of great interest in this setting.
Patients and methods
Between 1995 and 2002, 40 children received fully haplomismatched marrow from a family member in the Pediatric Immuno-Hematology Unit at Necker Hospital. All presented inherited disorders defined as SCID (n ¼ 32), or other primary immunodeficiency (n ¼ 8). In our analysis, we considered only first transplant recipients, given a CR with busulfan (8 mg/kg for seven patients, 20 or 16 mg/kg, respectively, for 33 children under or over 6 years of age), cyclophosphamide (200 mg/kg), anti-LFA1/anti-CD2 monoclonal antibodies, or, from 1998 onwards, rabbit antithymocyte globulin (ATG). All transplants were T-cell depleted using monoclonal antibodies, or CD34 þ selection from 1996.
HLA-A, -B, -C, -DR, and -DQ genotyping was performed in all donor-recipient pairs. The donor potential to exert NK alloreactivity against the recipient was defined by the presence of HLA class I KIR ligand incompatibility in the GVH direction 3 and by KIR genotyping. 1 The characteristics of the patients are given in Table 1 . All donors who, according to HLA mismatch with the recipient, had the potential to exert alloreactivity, also possessed the KIR gene involved in NK allorecognition of recipients. Patients were therefore divided into two groups according to the potential to exert alloreactivity. The mean age at the time of transplantation, method of T-cell depletion, and number of T cells injected did not significantly differ between the two patient groups. Engraftment was evaluated only in patients who survived for more than 1 month, and was defined by neutrophil count over 500 ml À1 and by the presence of mixed or complete donor chimerism evaluated by VNTR or karyotype analysis. GVHD was graded according to consensus criteria, with histological documentation whenever possible. Primary engraftment and GVHD were analyzed using two-tailed Fisher's exact tests.
Results and discussion
Out of the 40 patients 38 were evaluated, as two patients died within 1 month of transplantation. Primary engraftment was achieved in 24 (63%) patients. Among 23 patients fully analyzed for engraftment, 17 and six presented complete and mixed donor chimerism, respectively. Grade II-IV aGVHD occurred in 11/24 (45.8%). Overall survival was 21/40 (52.5%). Infection was the main cause of death (eight of 19 deaths, 42%).
We compared outcomes in patients transplanted from donors without (n ¼ 25) or with (n ¼ 13) potential donor-vsrecipient NK cell alloreactivity. Predicted NK cell alloreactivity was related to HLA-C mismatches in seven cases, to HLA-BW4 mismatch in five cases, and to HLA-A mismatch in only one case ( Table 2) . No difference was found in engraftment rate (61.5 vs 64%) or in full donortype chimerism (75 vs 74%). A trend towards a lower incidence of grade II-IV aGVHD in the 13 patients transplanted from donors with potential NK alloreactivity did not reach significance (37.5 vs 50%, P ¼ 0.68).
Since several patients in our series demonstrated mixed chimerism and had diseases that can preserve the NK cell lineage, we reasoned that NK alloreactivity might also occur in the HVG direction and thus jeopardize engraftment. In all, 30 patients who had significant numbers of functional NK cells at the time of transplantation (ie, after exclusion of patients with NK-negative SCID, leukocyte adhesion-LFA1 deficiency or familiar lymphohistiocytosis) were grouped according to the presence (n ¼ 15) or absence (n ¼ 15) of recipient potential to exert NK alloreactivity against the donor. The rate of engraftment was the same in both groups (60%).
A prospective study showed that when haploidentical donors displayed donor-vs-recipient alloreactive NK cells in their repertoires, NK cell alloreactivity had a beneficial impact on outcome in adults given haploidentical T-celldepleted transplants for high-risk acute myeloid leukemia after a myeloablative CR. 3 The results of the present retrospective study in children with inherited disorders, who underwent HCT after nonmyeloablative conditioning, The donor allele predicting donor-vs-recipient potential to exert NK alloreactivity in each of the 13 pairs is underlined.
differ from these results. Indeed, several retrospective attempts to assess the benefits of NK cell alloreactivity in KIR ligand-mismatched unrelated-donor HCT for hematological malignancies have provided discrepant results. [4] [5] [6] Differences in diagnoses, CRs, graft composition, and GVHD prophylaxis may account for these controversial results in patients who were all transplanted for malignant hematological diseases. In our patients, no post-transplant immune suppression was given as GVHD prophylaxis. The T-cell depletion procedure varied with time, resulting in different levels of depletion, with an overall mean number of injected T cells of 6 Â 10 4 /kg, which is higher than in the Ruggeri et al 3 study. Therefore, T-cell alloreactivity due to the HLA mismatch might have obscured NK cell alloreactivity, as recently observed in pediatric patients with hematological malignancies. 6 However, the percentage of patients who received o3 Â 10 4 /kg T cells was almost the same in the two patient groups (67% in patients with and 72% in those without KIR-ligand mismatch). ATG-based GVHD prophylaxis has been proposed as a means of facilitating recovery of donor NK cells. 4 A majority of our patients in both groups received ATG (8/13 in patients with and 12/25 without KIR-ligand mismatch). Others received anti-LFA-1 or anti-CD2 antibodies in the CR, which might have prevented NK cell binding to recipient targets. Nevertheless, the distribution of patients who received anti-LFA1 or anti-CD2 antibodies in both groups was not significantly different (4/13, 30.8% and 10/23, 43.5%, respectively) and could not explain these results.
Other reasons could explain our failure to detect a KIRepitope mismatch advantage in patients with inherited diseases. First, the nonmyeloablative CR used in seven SCID patients could leave more residual recipient target cells for the donor NK cells to ablate. However, when excluding these patients (three patients with and four without KIR mismatch treated with BU 8 mg/kg), no difference in engraftment rate, complete donor chimerism, or aGvHd Xgrade II was found between the two groups. Second, the lack of full donor-type chimerism may prevent the in vivo post-transplant generation of the alloreactive NK cells. Moreover, a recent update of NK alloreactive donor selection criteria showed that NK alloreactivity can be predicted reliably for HLA-C mismatches, but less so for HLA-B and HLA-A mismatches. 7 As alloreactivity cannot be confirmed without NK cloning and cytotoxicity assays against recipient targets, which is not possible retrospectively, further prospective studies are warranted.
In conclusion, despite these limitations, our single-center study conducted in pediatric patients who received a similar type of CR suggests that the beneficial effect of donor potential to exert NK cell alloreactivity on engraftment of haploidentical HCT is not applicable to children with inherited diseases. Although the incidence of aGVHD tended to be lower in patients transplanted from KIR ligand mismatched donors, large prospective studies are needed to address this issue.
